PTC Therapeutics
PTCT
199 hedge funds and large institutions have $2.44B invested in PTC Therapeutics in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 78 increasing their positions, 62 reducing their positions, and 27 closing their positions.
67% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 27
26% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 62
8% more funds holding
Funds holding: 184 → 199 (+15)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2% less capital invested
Capital invested by funds: $2.48B → $2.44B (-$42.6M)
7.17% less ownership
Funds ownership: 111.25% → 104.08% (-7.2%)
11% less call options, than puts
Call options by funds: $5.76M | Put options by funds: $6.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$10.1M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$8.1M |
| 3 |
Jane Street
New York
|
+$8.01M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$7.83M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$7.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$44.1M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$44M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$31.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$22.4M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$22.3M |
PTCT Hedge Fund Activity: Q2 2024 in Review
199 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2024, worth a combined $2.44B — down 1.7% from $2.48B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new PTCT positions and 27 closed out — a net gain of 18 holders — while 78 added to existing stakes and 62 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $10.1M. The largest seller was State Street, cutting an estimated $44.1M.
- 199 institutional investors held PTC Therapeutics (PTCT) as of Q2 2024, up from 184 in Q1 2024.
- Funds reported $2.44B of PTC Therapeutics stock for Q2 2024, down 1.7% quarter-over-quarter.
- 45 funds opened new PTC Therapeutics positions in Q2 2024 and 27 closed out, a net change of +18 holders.
- The largest PTC Therapeutics buyer in Q2 2024 was Goldman Sachs, an estimated $10.1M added.
- The largest PTC Therapeutics seller in Q2 2024 was State Street, an estimated $44.1M sold.
Based on aggregated 13F filings for Q2 2024.